SCHEMBL3557862

SCHEMBL3557862

CN(C)CCOc1cn(S(=O)(=O)c2ccc(F)cc2)c2cc(Cl)ccc12

nearest known ligand 0.70

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 9/20 0.61
▸ LSS P48449 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3555530 0.94 HTR6 (0.52) HTR6
SCHEMBL3562868 0.92 HTR6 (0.61) HTR6
SCHEMBL3560878 0.91 HTR6 (0.49) HTR6
SCHEMBL3558264 0.90 HTR6 (0.52) HTR6
SCHEMBL3567890 0.89 HTR6 (0.52) HTR6
SCHEMBL3563464 0.89 HTR6 (0.53) HTR6
SCHEMBL3564779 0.86 HTR6 (0.49) HTR6
SCHEMBL3563421 0.85 HTR6 (0.76) HTR6
SCHEMBL3567585 0.85 HTR6 (0.57) HTR6
SCHEMBL3552252 0.83 HTR6 (0.67) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 — — EP claimed
US-7507835-B2 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD. (IN) 2009-03-24 — — US claimed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 — — EP claimed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 — — WO claimed
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 — — EP disclosed
US-7718690-B2 N-arylsulfonyl-3-aminoalkoxyindoles RAMAKRISHNA VENKATA SATYA NIROGI 2010-05-18 — — US disclosed
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2009-05-21 — — US disclosed
US-7507835-B2 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD. (IN) 2009-03-24 — — US disclosed
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2006-08-03 — — US disclosed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 — — EP disclosed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT HTR6 56/4885LSS 294/4885
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT HTR6 56/4885LSS 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback